Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

DON'T BUY

Probably has a little better pipeline coming then Pfizer (PFE-N), so may be a little bit better growth. Still very modest growth for a great company but not cheap enough to buy it here when you can get companies with good yields and good growth at reasonable prices.

BUY

(Market Call Minute.) Likes the group in general.

DON'T BUY

Pharma have been one of the best performing sectors last year. Good focus. Going forward, their issue is the large drugs going off patent. He does not see the potential going forward. He prefers diagnostics or nutritionals.

BUY

(Market Cal Minute) $57.78, 51% upside.

HOLD

Had a whole lot of problems with patent expiration. Now they have had their big patent expirations out of the way. Doesn’t know what is going to happen in the next couple of months.

BUY

(Market Call Minute.) Ranks very well. Nice and safe dividend of 3.8%.

DON'T BUY

Trading at about 12X earnings which is not really expensive. Has over 3% dividend. The problem is that most people don’t expect the earnings to grow and are actually going to decline over the next few years. Would prefer Abbot Labs (ABT-N) or Teva Pharmaceuticals (TEVA-N).

HOLD

Chart shows a long, long sideways market followed by an outstanding pop. Chart is showing a parabolic move but the trend is up. Typically when a stock moves quite a bit off a trend line, be prepared that it could return to the trend line. If you are a longer-term investor, stay with the story as long as it doesn’t break the trend line.

COMMENT

US health care valuations are very, very attractive. They have reasonable PE’s and good dividends. This is all about the 3.8% dividend. He would prefer something with a cheaper valuation and better dividend growth.

COMMENT

On a seasonal pattern, healthcare stocks should do well coming into the summer months. This one has kind of marked time for a few months. Nice dividend at 4.3%. (See Top Picks.)

WEAK BUY

Likes the group, nice dividends. They trade at a discount. There are concerns about generic competition and blockbuster drugs coming off patients. But he sees that as built into the price and MRK is attractive to invest in. He has preferred some other companies in the space over MRK.

DON'T BUY

No drug pipeline that PFE has. Jut doesn’t have the future growth, so he prefers PFE. Bristol Myers would be a second choice with a good pipeline.

BUY

Every Canadian should have exposure to health care and it is very hard to get this in Canada. Not his favourite name but you can’t go too far wrong. Earnings are finally recovering. Good dividend growth. There is a lack of new drugs, but they will come, over time.

PAST TOP PICK

(Top Pick Feb 17/11, Up 21.55%) Still likes it.

DON'T BUY

Still relatively inexpensive. They are in restrained growth at this point. Has come off recently because all of the pharmas had a pretty strong year last year and people are shifting into the more resource stocks. It's a defensive stock so there is slower growth.

Showing 181 to 195 of 304 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)